2016
DOI: 10.3945/jn.116.231910
|View full text |Cite
|
Sign up to set email alerts
|

A Slow- Compared with a Fast-Release Form of Oral Arginine Increases Its Utilization for Nitric Oxide Synthesis in Overweight Adults with Cardiometabolic Risk Factors in a Randomized Controlled Study

Abstract: In overweight adults with the HTW phenotype, a slow- compared with a fast-release form of oral arginine markedly favors the utilization of arginine for NO synthesis. The utilization of low-dose, slow-release arginine for NO synthesis is higher in overweight adults with the HTW phenotype than in healthy controls, suggesting that the sensitivity of NO synthesis to the dietary arginine supply increases with cardiometabolic risk. The trial was registered at clinicaltrials.gov as NCT02352740.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 11 publications
(2 citation statements)
references
References 55 publications
(90 reference statements)
0
2
0
Order By: Relevance
“…For instance, the acute oral administration of arginine (9 g/day) has been shown to be not successful in inducing an effective NO production [ 216 ]. Instead, chronic administration of oral arginine (e.g., vials containing arginine salts-free 1.66 g/20 mL), has been shown to favor the utilization of arginine for NO synthesis [ 300 ], and we have data showing that oral arginine (3 g/day of Bioarginina ® , Farmaceutici Damor, 2 vials/day) improves endothelial function in hypertensive patients via the regulation of non-coding RNAs (Gambardella et al, personal communication). Large, prospective randomized clinical trials are needed to better define the target population for arginine supplementation, alongside with correct dosage definitions.…”
Section: Conclusion and Perspective: Arginine As A Therapeutic Tomentioning
confidence: 99%
“…For instance, the acute oral administration of arginine (9 g/day) has been shown to be not successful in inducing an effective NO production [ 216 ]. Instead, chronic administration of oral arginine (e.g., vials containing arginine salts-free 1.66 g/20 mL), has been shown to favor the utilization of arginine for NO synthesis [ 300 ], and we have data showing that oral arginine (3 g/day of Bioarginina ® , Farmaceutici Damor, 2 vials/day) improves endothelial function in hypertensive patients via the regulation of non-coding RNAs (Gambardella et al, personal communication). Large, prospective randomized clinical trials are needed to better define the target population for arginine supplementation, alongside with correct dosage definitions.…”
Section: Conclusion and Perspective: Arginine As A Therapeutic Tomentioning
confidence: 99%
“…However, arginine is made available slowly from dietary proteins, which may affect its utilization for NO synthesis. In this respect, we showed in another study that in adults with the hypertriglyceridemic waist (HTW) 8 phenotype, sustained-release (SR) arginine, which mimics the kinetics of dietary arginine, was used more efficiently for NO synthesis than an immediate-release form (29). At a low level of intake, SR-arginine has been shown to improve endothelial function under fasting conditions (12).…”
Section: Introductionmentioning
confidence: 99%